Ocular Therapeutix Inc’s recently made public that its Chief Medical Officer Waheed Nadia unloaded Company’s shares for reported $0.11 million on Jun 02 ’25. In the deal valued at $8.05 per share,13,861 shares were sold. As a result of this transaction, Waheed Nadia now holds 206,805 shares worth roughly $1.84 million.
Then, NADIA K. WAHEED bought 13,861 shares, generating $111,524 in total proceeds.
Before that, Nayak Sanjay sold 1,862 shares. Ocular Therapeutix Inc shares valued at $13,351 were divested by the Chief Strategy Officer at a price of $7.17 per share. As a result of the transaction, Nayak Sanjay now holds 281,623 shares, worth roughly $2.51 million.
William Blair initiated its Ocular Therapeutix Inc [OCUL] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Needham began covering OCUL with “Buy” recommendation on March 11, 2025. Scotiabank started covering the stock on October 16, 2024. It rated OCUL as “a Sector outperform”.
Price Performance Review of OCUL
On Tuesday, Ocular Therapeutix Inc [NASDAQ:OCUL] saw its stock jump 0.11% to $8.91. Over the last five days, the stock has gained 6.96%. Ocular Therapeutix Inc shares have risen nearly 4.33% since the year began. Nevertheless, the stocks have risen 71.35% over the past one year.
How much short interest is there in Ocular Therapeutix Inc?
A steep rise in short interest was recorded in Ocular Therapeutix Inc stocks on 2025-05-15, dropping by -0.27 million shares to a total of 13.83 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 14.1 million shares. There was a decline of -1.95%, which implies that there is a negative sentiment for the stock.
